RET and non-small cell lung carcinoma: To the best of our knowledge, our case demonstrates, for the first time, a clinical and radiological response to frontline highly selective RETi selpercatinib, expanding the spectrum of potential oncogenic <i>RET</i> fusion partners in newly diagnosed NSCLC patients.